You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: November 22, 2024

FLUTICASONE PROPIONATE AND SALMETEROL XINAFOATE Drug Patent Profile


✉ Email this page to a colleague

« Back to Dashboard


Which patents cover Fluticasone Propionate And Salmeterol Xinafoate, and when can generic versions of Fluticasone Propionate And Salmeterol Xinafoate launch?

Fluticasone Propionate And Salmeterol Xinafoate is a drug marketed by Hikma and Teva Pharms Usa and is included in two NDAs.

The generic ingredient in FLUTICASONE PROPIONATE AND SALMETEROL XINAFOATE is fluticasone propionate; salmeterol xinafoate. There are twenty-nine drug master file entries for this compound. Twelve suppliers are listed for this compound. Additional details are available on the fluticasone propionate; salmeterol xinafoate profile page.

DrugPatentWatch® Litigation and Generic Entry Outlook for Fluticasone Propionate And Salmeterol Xinafoate

A generic version of FLUTICASONE PROPIONATE AND SALMETEROL XINAFOATE was approved as fluticasone propionate; salmeterol xinafoate by HIKMA on December 17th, 2020.

  Sign Up

AI Research Assistant
Questions you can ask:
  • What is the 5 year forecast for FLUTICASONE PROPIONATE AND SALMETEROL XINAFOATE?
  • What are the global sales for FLUTICASONE PROPIONATE AND SALMETEROL XINAFOATE?
  • What is Average Wholesale Price for FLUTICASONE PROPIONATE AND SALMETEROL XINAFOATE?
Summary for FLUTICASONE PROPIONATE AND SALMETEROL XINAFOATE
Drug patent expirations by year for FLUTICASONE PROPIONATE AND SALMETEROL XINAFOATE
Recent Clinical Trials for FLUTICASONE PROPIONATE AND SALMETEROL XINAFOATE

Identify potential brand extensions & 505(b)(2) entrants

SponsorPhase
Novartis PharmaceuticalsPhase 3
Imperial College LondonPhase 4
European Research CouncilPhase 4

See all FLUTICASONE PROPIONATE AND SALMETEROL XINAFOATE clinical trials

Pharmacology for FLUTICASONE PROPIONATE AND SALMETEROL XINAFOATE

US Patents and Regulatory Information for FLUTICASONE PROPIONATE AND SALMETEROL XINAFOATE

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Hikma FLUTICASONE PROPIONATE AND SALMETEROL XINAFOATE fluticasone propionate; salmeterol xinafoate POWDER;INHALATION 203433-001 Dec 17, 2020 AB RX No No ⤷  Sign Up ⤷  Sign Up ⤷  Sign Up
Teva Pharms Usa FLUTICASONE PROPIONATE AND SALMETEROL XINAFOATE fluticasone propionate; salmeterol xinafoate POWDER;INHALATION 213948-001 Dec 13, 2021 AB RX No No ⤷  Sign Up ⤷  Sign Up ⤷  Sign Up
Hikma FLUTICASONE PROPIONATE AND SALMETEROL XINAFOATE fluticasone propionate; salmeterol xinafoate POWDER;INHALATION 203433-002 Dec 17, 2020 AB RX No No ⤷  Sign Up ⤷  Sign Up ⤷  Sign Up
Hikma FLUTICASONE PROPIONATE AND SALMETEROL XINAFOATE fluticasone propionate; salmeterol xinafoate POWDER;INHALATION 203433-003 Dec 19, 2023 AB RX No No ⤷  Sign Up ⤷  Sign Up ⤷  Sign Up
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

EU/EMA Drug Approvals for FLUTICASONE PROPIONATE AND SALMETEROL XINAFOATE

Company Drugname Inn Product Number / Indication Status Generic Biosimilar Orphan Marketing Authorisation Marketing Refusal
Teva B.V. Airexar Spiromax salmeterol xinafoate, fluticasone propionate EMEA/H/C/004267
Airexar Spiromax is indicated for use in adults aged 18 years and older only.AsthmaAirexar Spiromax is indicated for the regular treatment of patients with severe asthma where use of a combination product (inhaled corticosteroid and long-acting β2 agonist) is appropriate:- patients not adequately controlled on a lower strength corticosteroid combination productor- patients already controlled on a high dose inhaled corticosteroid and long-acting β2 agonist.Chronic Obstructive Pulmonary Disease (COPD)Airexar Spiromax is indicated for the symptomatic treatment of patients with COPD, with a FEV1
Withdrawn no no no 2016-08-18
>Company >Drugname >Inn >Product Number / Indication >Status >Generic >Biosimilar >Orphan >Marketing Authorisation >Marketing Refusal

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.